The Romanian Competition Council has fined Roche a total of €12.8m for abusing a dominant position on the oncology drugs market by hindering the market entry of versions of MabThera (rituximab), Herceptin (trastuzumab) and Tarceva (erlotinib).
Roche said it would appeal against the decision, which it described as “biased
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?